• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cancers, Vol. 14, Pages 3726: Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches
In conclusion, a compound screen together with a functional genomic approach identified Src as a potential chemosensitising target in OAC, which could be assessed in a clinical study for poor prognosis OAC patients.
Source: Cancers - July 30, 2022 Category: Cancer & Oncology Authors: Niamh H. McCabe Leanne Stevenson Enya Scanlon Rosalie Douglas Susanna Kennedy Oliver Keminer Bj örn Windshügel Daniela Zisterer Richard D. Kennedy Jaine K. Blayney Richard C. Turkington Tags: Article Source Type: research

Cancers, Vol. 13, Pages 3903: Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Rakesh Heer Cisplatin-based neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy for muscle-invasive bladder cancer (MIBC) patients. Despite a 5–10% survival benefit, some patients do not respond and experience substantial toxicity and delay in surgery. To date, there are no clinically approved biomarkers predictive of response to NAC and their identification is urgently required for more precise delivery of care. To address this issue, a multi-methods analysis approach of machine learning and differential gene expression analysis was undertaken on a cohort of 30 MIBC cases highly selected for an...
Source: Cancers - August 2, 2021 Category: Cancer & Oncology Authors: Anastasia C. Hepburn Nicola Lazzarini Rajan Veeratterapillay Laura Wilson Jaume Bacardit Rakesh Heer Tags: Article Source Type: research

298PTargeting CDCA3 to improve chemotherapy response in triple negative breast cancer patients
ConclusionsOur data highlight CDCA3 as a novel prognostic factor in TNBC that modulates sensitivity to chemotherapy. These findings point to the therapeutic potential of targeting CDCA3 in TNBC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
CONCLUSION: Our study suggested that Nek2B can bind to β-catenin and the co-expression correlated with TNBC patients poor prognosis. It appears that Nek2B and β-catenin might synergize to promote chemotherapy resistance. PMID: 31174562 [PubMed - in process]
Source: Clinical Genitourinary Cancer - June 6, 2019 Category: Cancer & Oncology Authors: Shen H, Yan W, Yuan J, Wang Z, Wang C Tags: J Exp Clin Cancer Res Source Type: research

Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway.
In conclusion, IFNβ leads to apoptosis in NPC cells in an autocrine way via the induction of TRAIL expression and subsequent activation of the TRAIL-signaling pathway. The mechanism described could at least partly explain the clinical benefit of IFNβ in the treatment of NPC. Further studies in a mouse-xenograft model are warranted to substantiate this effect in vivo. PMID: 29581840 [PubMed]
Source: Oncotarget - March 29, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers.
CONCLUSIONS: we identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes and platins. RB positivity and high expression of TYMP were significantly associated with capecitabine response. PMID: 29463559 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 20, 2018 Category: Cancer & Oncology Authors: Marangoni E, Laurent C, Coussy F, El Botty R, Chateau-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Némati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noël A, Salomon A, Lae M, Decaudin D, Roman-Roman S, B Tags: Clin Cancer Res Source Type: research

Abstract B08: ER chaperone GRP78 increases chemoresistance in pancreatic ductal adenocarcinoma
Conclusions: Collectively, our data show that GRP78 expression promotes chemoresistance in PDAC and therapeutic strategies blocking the activity of GRP78 increase the efficacy of currently available therapies.Citation Format: Jenifer B. Gifford, Wei Huang, Ann E. Zeleniak, Antreas Hindoyan, Hong Wu, Timothy R. Donahue, Reginald Hill.{Authors}. ER chaperone GRP78 increases chemoresistance in pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr B08.
Source: Cancer Research - December 13, 2016 Category: Cancer & Oncology Authors: Jenifer B. Gifford, Wei Huang, Ann E. Zeleniak, Antreas Hindoyan, Hong Wu, Timothy R. Donahue, Reginald Hill Tags: Molecular Drivers of Pancreatic Cancer Biology and Metastasis Source Type: research

Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells
Conclusion: Survivin siRNA combined with the neoadjuvant chemotherapy can significantly enhance the sensitivity of MCF-7 cells to chemotherapeutics and cell apoptosis. This technology has important potential value in the therapeutic study of breast cancer.
Source: Journal of Cancer Research and Therapeutics - February 15, 2016 Category: Cancer & Oncology Authors: Honglin DongLuyu YaoWeilin BiFusheng WangWei SongYonggang Lv Source Type: research

Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro
Abstract Toll-like receptor 9 (TLR9) is a cellular DNA-receptor widely expressed in cancers. We previously showed that synthetic and self-derived DNA fragments induce TLR9-mediated breast cancer cell invasion in vitro. We investigated here the invasive effects of two nuclease-resistant DNA fragments, a 9-mer hairpin, and a G-quadruplex DNA based on the human telomere sequence, both having native phosphodiester backbone. Cellular uptake of DNAs was investigated with immunofluorescence, invasion was studied with Matrigel-assays, and mRNA and protein expression were studied with qPCR and Western blotting and prot...
Source: Breast Cancer Research and Treatment - January 18, 2016 Category: Cancer & Oncology Source Type: research

Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy
Background: Multi-drug Resistance associated Protein-1 (MRP1) can export chemotherapeutics from cancer cells and is implicated in chemoresistance, particularly as is it known to be up-regulated by chemotherapeutics. Our aims in this study were to determine whether activation of Notch signalling is responsible for chemotherapy-induced MRP1 expression Notch in breast cancers, and whether this pathway can be manipulated with an inhibitor of Notch activity. Methods: MRP1 and Notch1 were investigated in 29 patients treated with neoadjuvant chemotherapy (NAC) for breast cancer, using immunohistochemistry on matched biopsy (pre-N...
Source: BMC Cancer - September 11, 2015 Category: Cancer & Oncology Authors: Baek KimSam StephenAndrew HanbyKieran HorganSarah PerryJulie RichardsonElizabeth RoundhillElizabeth ValleleyEldo VergheseBethany WilliamsJames ThorneThomas Hughes Source Type: research

Abstract 2225: c-Myc and Frizzled 8 play a major role in the regulation of cancer stem cells and drug resistance in triple-negative breast cancer
In this study, we have found that c-Myc overexpression increased FZD8 expression, and its downstream signaling and together protect the cells from drug mediated cell death compared to vector transfected cells. c-Myc over-expressing cells do not show increased mammosphere formation; the numbers of CSCs per mammosphere are much higher compared to vector transfected controls. CDK inhibitor (dinaciclib) enhanced the cell death in c-Myc over expressing non-CSCs with minimal effect on CSCs. Inhibition of c-Myc using siRNA reduced c-Myc, FZD-8 and CSCs and enhanced sensitivity of cells to cisplatin plus TRAIL. Taken together, our...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Yin, S., Cheriyan, V. T., Rishi, A. K., Reddy, K. B. Tags: Tumor Biology Source Type: research

Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance
Conclusion: Acquired L/LT resistance in the two BT474 R lines is due to selection of HER2 L755S subclones present in parental cells. The higher HER2 L755S levels in BT474 parentals compared with other parentals, and detection of its subclonal presence in a pre-treatment HER2+ BC patient, suggest that sensitive mutation detection methods will be needed to identify patients with potentially actionable HER family mutations in primary tumor. Treating this patient group with an irreversible TKI like Afa may prevent resistance and improve clinical outcome of this subset of HER2+ BC.Citation Format: Xiaowei Xu, Agostina Nardone, ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Xu, X., Nardone, A., Hu, H., Qin, L., Nanda, S., Heiser, L., Wang, N., Covington, K., Chen, E., Renwick, A., Mitchell, T., Shea, M., Wang, T., De Angelis, C., Contreras, A., Gutierrez, C., Fuqua, S., Chamness, G., Shaw, C., Li, M., Wheeler, D., Hilsenbeck Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 920: Secreted frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC)
Conclusion: We suggest SFRP1 as a novel predictive marker of chemotherapy sensitivity to taxane, anthracycline and platinum-containing chemotherapy independent of Ki67 expression. Further on, we have shown the influence of SFRP1 on cancerous characteristics thus, suggesting SFRP1 as potential prognostic marker. Molecular role of SFRP1 may be the influence on enrichment of cancer stem cell population which are known to be resistant against chemotherapeutics and radiation and are usually slow proliferating. Interestingly, the mTOR/PI3K signaling might be activated via loss of SFRP1 which could display an opportunity for pati...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Huelsewig, C., Bernemann, C., Ruckert, C., Kiesel, L., Goette, M., Rody, A., Pusztai, L., Hempel, G., Liedtke, C. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research

Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling
Conclusion: We could firstly show that SFRP1 strongly correlates with the triple negative breast cancer subtype and secondly, that SFRP1 might be used as a marker stratifying patients to positively respond to neoadjuvant chemotherapy. The mechanisms by which tumor suppressor SFRP1 influences carcinogenic properties of cancer cells do not rely on Wnt signaling, thereby demonstrating the complexity of tumor associated signaling pathways.
Source: Molecular Cancer - July 17, 2014 Category: Cancer & Oncology Authors: Christof BernemannCarolin HülsewigChristian RuckertSarah SchäferLena BlümelGeorg HempelMartin GötteBurkhard GrevePeter BarthLudwig KieselCornelia Liedtke Source Type: research

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers
Abstract: Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC analyses of each gene expression according to TP53 mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 w...
Source: Molecular Oncology - January 13, 2014 Category: Cancer & Oncology Authors: Balázs Győrffy, Giulia Bottai, Jacqueline Lehmann-Che, György Kéri, László Őrfi, Takayuki Iwamoto, Christine Desmedt, Giampaolo Bianchini, Nicholas C. Turner, Hugues de Thè, Fabrice André, Christos Sotiriou, Gabriel N. Hortobagyi, Angelo Di Leo, Tags: Research articles Source Type: research